

Full fist of Publications, Prof. Dr. Robert Rieben, September 2021**Peer Reviewed, Original Papers**

114. Olariu R, Tsai C, Abd El Hafez M, Milusev A, Banz Y, Lese I, Leckenby JI, Constantinescu M, Rieben R, Vögelin E, Taddeo A. Presence of Donor Lymph Nodes Within Vascularized Composite Allografts Ameliorates VEGF-C-mediated Lymphangiogenesis and Delays the Onset of Acute Rejection. *Transplantation*. 2021 Aug 1;105(8):1747-1759. doi: 10.1097/TP.0000000000003601. PMID: 34291766
113. Reichart B, Längin M, Radan J, Mokelke M, Buttgereit I, Ying J, Fresch AK, Mayr T, Issl L, Buchholz S, Michel S, Illgass Reinhard, Mihalj M, Egerer S, Bähr A, Kessler B, Kemter E, Kurome M, Zakhartchenko V, Steen S, Sjöberg, Paskevicius A, Krüger L, Fiebig U, Denner J, Godehardt AW, Tönjes RR, Milusev A, Sfriso R, **Rieben R**, Walz C, Kirchner T, Ayares D, Lampe K, Schönmann U, Hagl C, Wolf E, Klymiuk N, Abicht JM, Brenner P. Pig-to-non-human primate heart transplantation: the final step toward clinical xenotransplantation? *Journal of Heart and Lung Transplantation*, 2020. DOI: <https://doi.org/10.1016/j.healun.2020.05.004>
112. Wüthrich T, Lese I, Haberthür D, Zubler C, Hlushchuk R, Hewer E, Maistriaux L, Gianello P, Lengelé B, **Rieben R**, Vögelin E, Olariu R, Duisit J, Taddeo A. Development of vascularized nerve scaffold using perfusion-decellularization and recellularization. *Mater Sci Eng C Mater Biol Appl*. 2020 Dec;117:111311. doi: 10.1016/j.msec.2020.111311. Epub 2020 Aug 5. PMID: 32919672.
111. Wilbs J, Kong XD, Middendorp SJ, Prince R, Cooke A, Demarest CT, Abdelhafez MM, Roberts K, Umei N, Gonschorek P, Lamers C, Deyle K, **Rieben R**, Cook KE, Angelillo-Scherrer A, Heinis C. Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs. *Nat Commun*. 2020 Aug 4;11(1):3890. doi: 10.1038/s41467-020-17648-w. PMID: 32753636; PMCID: PMC7403315.
110. Längin M, Reichart B, Steen S, Sjöberg T, Paskevicius A, Liao Q, Qin G, Mokelke M, Mayr T, Radan J, Issl L, Buttgereit I, Ying J, Fresch AK, Panelli A, Egerer S, Bähr A, Kessler B, Milusev A, Sfriso R, **Rieben R**, Ayares D, Murray PJ, Ellgass R, Walz C, Klymiuk N, Wolf E, Abicht JM, Brenner P. Cold non-ischemic heart preservation with continuous perfusion prevents early graft failure in orthotopic pig-to-baboon xenotransplantation. *Xenotransplantation*. 2020 Aug 25:e12636. doi: 10.1111/xen.12636. PMID: 32841431.
109. Denner J, Längin M, Reichart B, Krüger L, Fiebig U, Mokelke M, Radan J, Mayr T, Milusev A, Luther F, Sorvillo N, **Rieben R**, Brenner P, Walz C, Wolf E, Roshani B, Stahl-Hennig C, Abicht JM. Impact of porcine cytomegalovirus on long-term orthotopic cardiac xenotransplant survival. *Sci Rep*. 2020 Oct 16;10(1):17531. doi: 10.1038/s41598-020-73150-9. PMID: 33067513; PMCID: PMC7568528.
108. Wuensch A, Kameritsch P, Sfriso R, Jemiller EM, Bähr A, Kurome M, Kessler B, Kemter E, Pupatt C, Reichart B, **Rieben R**, Wolf E, Klymiuk N. Genetically encoded Ca²⁺-sensor reveals details of porcine endothelial cell activation upon contact with human serum [published online ahead of print, 2020 Feb 14]. *Xenotransplantation*. 2020;e12585. doi:10.1111/xen.12585.
107. Boligan KF, Oechtering J, Keller CW, Peschke B, **Rieben R**, Bovin N, Kappos L, Cummings RD, Kuhle J, von Gunten S, Lünemann JD. Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS. *Neurology Neuroimmunol Neuroinflamm*. 2020;7(2):e676. Published 2020 Feb 3. doi:10.1212/NXI.0000000000000676.

106. Sfriso R, Rieben R. 3D Cell-Culture Models for the Assessment of Anticoagulant and Anti-Inflammatory Properties of Endothelial Cells. *Methods Mol Biol.* 2020;2110:83-97. doi:10.1007/978-1-0716-0255-3_6.
105. Fischer K, Rieblingher B, Hein R, Sfriso R, Zuber J, Fischer A, Klinger B, Liang W, Flisikowski K, Kurome M, Zakhartchenko V, Kessler B, Wolf E, **Rieben R**, Schwinzer R, Kind A, Schnieke A. Viable pigs after simultaneous inactivation of porcine MHC class I and three xenoreactive antigen genes GGTA1, CMAH and B4GALNT2. *Xenotransplantation.* 2019 Oct 8:e12560. DOI: 10.1111/xen.12560.
104. Jandus P, Frias Boligan K, Smith DF, de Graauw E, Grimbacher B, Jandus C, Abdelhafez MM, Despont A, Bovin N, Simon D, **Rieben R**, Simon HU, Cummings RD, von Gunten S. The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies (PADs). *Blood.* 2019 Sep 19. pii: blood.2019001705. DOI: 10.1182/blood.2019001705.
103. Sutter D, Dzhonova DV, Prost JC, Bovet C, Banz Y, Rahnfeld L, Leroux JC, **Rieben R**, Voegelin E, Plock JA, Luciani P, Taddeo A, Schnider T. Delivery of Rapamycin using in situ forming implants promotes Immunoregulation and vascularized composite allograft survival. *Sci Rep* 2019 9:9296. DOI: 10.1038/s41598-019-45759-y.
102. Zandi S, Pfister IB, Traine PG, Tappeiner C, Despont A, **Rieben R**, Skowronka M, Garweg JG. Biomarkers for PVR rhegmatogenous retinal detachment. *PLoS One.* 2019 Apr;14(4):e0214674. DOI: 10.1371/journal.pone.0214674.
101. Garweg JG, Zandi S, Pfister I, **Rieben R**, Skowronska M, Tappeiner C. Cytokine profiles of phakic and pseudophakic eyes with primary retinal detachment. *Acta Ophthalmol.* 2018 Dec 18. DOI: 10.1111/aos.13998.
100. Zhang S, Shaw-Boden J, Banz Y, Bongoni AK, Taddeo A, Spirig R, Nolte MW, Cowan PJ, **Rieben R**. Effects of C1 inhibitor on endothelial cell activation in a rat hind limb ischemia-reperfusion injury model. *J Vasc Surg.* 2018 Dec;68(6S):209S-221S.e2. DOI: 10.1016/j.jvs.2017.10.072.
99. Längin M, Mayr T, Reichart B, Michel S, Buchholz S, Guethoff S, Dashkevich A, Baehr A, Egerer S, Bauer A, Mihalj M, Panelli A, Issl L, Ying J, Fresch AK, Buttgereit I, Mokelke M, Radan J, Werner F, Lutzmann I, Steen S, Sjöberg T, Paskevicius A, Qiuming L, Sfriso R, **Rieben R**, Dahlhoff M, Kessler B, Kemter E, Klett K, Hinkel R, Kupatt C, Falkenau A, Reu S, Ellgass R, Herzog R, Binder U, Wich G, Skerra A, Ayares D, Kind A, Schönmann U, Kaup FJ, Hagl C, Wolf E, Klymiuk N, Brenner P, Abicht JM. Consistent success in life-supporting porcine cardiac xenotransplantation. *Nature.* 2018 Dec;564(7736):430-433. DOI: 10.1038/s41586-018-0765-z.
98. Taddeo A, Tsai C, Vögelin E, **Rieben R**. Novel targeted drug delivery systems to minimize systemic immunosuppression in vascularized composite allotransplantation. *Curr Opin Organ Transplant.* 2018 Oct;23(5):568-576. DOI: 10.1097/MOT.0000000000000564.
97. Dzhonova D, Olariu R, Leckenby J, Dhayani A, Vemula PK, Prost JC, Banz Y, Taddeo A, **Rieben R**. Local release of tacrolimus from hydrogel-based drug delivery system is controlled by inflammatory enzymes in vivo and can be monitored non-invasively using in vivo imaging. *PLoS One.* 2018 Aug 30;13(8):e0203409. DOI: 10.1371/journal.pone.0203409.
96. Dzhonova D, Olariu R, Leckenby J, Banz Y, Prost JC, Dhayani A, Vemula PK, Voegelin E, Taddeo A, **Rieben R**. Local injections of tacrolimus-loaded hydrogel reduce systemic immunosuppression-related toxicity in vascularized composite allotransplantation. *Transplantation* 2018, Oct;102(10):1684-1694. DOI: 10.1097/TP.0000000000002283.

95. Sfriso R, Zhang S, Bichsel CA, Steck O, Despont A, Guenat OT, **Rieben R**. 3D artificial round section micro- vessels to investigate endothelial cells under physiological flow conditions. *Sci Rep* 2018, 8(1):5898. DOI 10.1038/s41598-018-24273-7.
94. Duisit J, Amiel H, Wüthrich T, Taddeo A, Dedriche A, Destoop V, Pardoent T, Bouzin C, Joris V, Magee D, Vögelin E, Harriman D, Dessim C, Orlando G, Behets C, **Rieben R**, Gianello P, Lengelé B. Perfusion-decellularization of human ear grafts enables ECM-based scaffolds for auricular vascularized composite tissue engineering, *Acta Biomaterialia* 2018. DOI: 10.1016/j.actbio.2018.04.009.
93. Abdelhafez MM, Shaw J, Wilbs J, Despont A, **Rieben R**. Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures. *J Vis Exp* 2018, (133), e56856. DOI 10.3791/56856.
92. Abicht JM, Sfriso R, Reichart B, Längin M, Gahle K, Puga Yung GL, Seebach JD, **Rieben R**, Ayares D, Wold E, Klymiuk N, Baehr A, Kind A, Mayr T, Bauer A. Multiple genetically modified GTKO/hCD46/HLA-E/hβ2-mg porcine hearts are protected from complement activation and natural killer cell infiltration during ex vivo perfusion with human blood. *Xenotransplantation*. 2018, e12390. DOI 10.1111/xen.12390.
91. Gygax E, Kaeser HU, Stalder M, Gahl B, **Rieben R**, Carrel T, Erdoes G. Type II Minimal-Invasive Extracorporeal Circuit for Aortic Valve Replacement: A Randomized Controlled Trial. *Artificial Organs* 2018, 00(00):00–00. DOI 10.1111/aor.13093.
90. Puga Yung G, Bongoni A, Pradier A, Madelon N, Papaserafeim M, Sfriso R, Ayares D, Wolf E, Klymiuk N, Bähr A, Constantinescu M, Vögelin E, Kiermeir D, Jenni HJ, **Rieben R**, Seebach JD. Release of pig leukocytes and reduced human NK cell recruitment during ex vivo perfusion of HLA-E/human CD46 double-transgenic pig limbs with human blood. *Xenotransplantation* 2017, e12357. DOI 10.1111/xen.12357.
89. Sfriso R, Bongoni A, Banz Y, Klymiuk N, Wolf E, **Rieben R**. Assessment of the anticoagulant and anti-inflammatory properties of endothelial cells using 3D cell culture and non-anticoagulated whole blood. *J Vis Exp* 2017, 127:e56227. DOI 10.3791/56227.
88. Olariu R, Denoyelle J, Leclère FM, Dzhonova DV, Gajanayake T, Banz Y, Hayoz M, Constantinescu M, **Rieben R**, Vögelin E, Taddeo A. Intra-graft injection of tacrolimus promotes survival of vascularized composite allotransplantation. *J Surg Res* 2017, 218:49–57. DOI 10.1016/j.jss.2017.05.046.
87. Duisit, J, Maistriaux L, Taddeo A, Orlando G, Joris V, Coche E, Behets C, Lerut J, Dessim C, Cossu G, Vögelin E, **Rieben R**, Gianello P, Lengelé B. Bioengineering a human face graft. The matrix of identity. *Ann Surg* 2017 Nov;266(5):754-764. DOI 10.1097/SLA.0000000000002396
86. Bongoni AK, Salvaris E, Nordling S, Klymiuk N, Wolf E, Ayares DL, **Rieben R**, Magnusson PU, Cowan PJ. Surface modification of pig endothelial cells with a branched heparin conjugate improves their compatibility with human blood. *Scientific Reports* 2017, 7:4450. DOI 10.1038/s41598-017-04898-w.
85. Abdelhafez MM, Shaw J, Sutter D, Schnider J, Banz Y, Jenni HJ, Voegelin E, Constantinescu MA, **Rieben R**. Effect of C1-INH on ischemia/reperfusion injury in a porcine limb ex vivo perfusion model. *Molecular Immunology* 2017, 88:11-6124. DOI 10.1016/j.molimm.2017.06.021.

84. Pischke SE, Gustavsen A, Orrem HL, Egge KH, Courivaud F, Fontenelle H, Despont A, Bongoni AK, **Rieben R**, Tønnessen TI, Nunn MA, Scott H, Skultad H, Barrat-Due A, Mollnes TE. Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function. *Basic Research in Cardiology* 2017, 112(3):20. DOI 10.1007/s00395-017-0610-9.
83. Zhang S, Wotzkow C, Bongoni AK, Shaw-boden J, Siegrist M, Taddeo A, Blank F, Hofstetter W, **Rieben R**. Role of the plasma cascade systems in ischemia/reperfusion injury of bone. *Bone* 2017, 97:278-286.
82. Kamat P, Vandenberghe S, Christen S, Bongoni AK, Meier B, **Rieben R***, Khattab A. Dexrazoxane shows no protective effect in the acute phase of reperfusion during myocardial infarction in pigs. *PLOS ONE* 2016, 11(12):e0168541.
*corresponding author
81. Zandi S, Tappeiner C, Pfister IB, Despont A, **Rieben R**, Garweg JG. Vitreal cytokine profile differences between eyes with epiretinal membranes or macular holes. *Invest Ophthalmol Vis Sci* 2016, 57:6320-6326.
80. Bongoni AK, Klymiuk N, Wolf E, Ayares D, **Rieben R**, Cowan PJ. Transgenic expression of human thrombomodulin inhibits HMGB1-induced porcine aortic endothelial cell activation. *Transplantation* 2016, 100:1871-1879.
79. Spirig A, Juon B, Banz Y, **Rieben R**, Vögelin E. Correlation between sonographic and in vivo measurement of A1 pulleys in trigger fingers. *Ultrasound in Medicine and Biology* 2016, 42(7):1482-1490.
78. Zuccarella-Hackl C, von Känel R, Thomas L, Kuebler P, Schmid JP, Mattle HP, Mono ML, **Rieben R**, Wiest R, Wirtz, PH. Higher macrophage superoxide anion production in coronary artery disease (CAD) patients with Type D personality. *Psychoneuroendocrinology* 2016, 68:186-193.
77. Zhang S, Duehrkop C, Plock J, **Rieben R**. Inhalation anesthesia of rats: Influence of the fraction of inspired oxygen on limb ischemia/reperfusion injury. *Laboratory Animals* 2015, 50(3):185-197.
76. Banz Y, Item GM, Vogt A, **Rieben R**, Candinas D, Beldi, G. Endothelial- and Platelet-derived Microparticles are generated during Liver Resection in Humans. *Journal of Investigative Surgery* 2015, 29(1):20-31.
75. Bongoni AK, Kiermeir D, Schnider J, Jenni HJ, Garimella PS, Bähr A, Klymiuk N, Wolf E, Ayares D, Voegelin E, Constantinescu MA, Seebach JD, **Rieben R**. Transgenic Expression of Human CD46 on Porcine Endothelium: Effect on Coagulation and Fibrinolytic Cascades During Ex Vivo Human-to-Pig Limb Xenoperfusions. *Transplantation* 2015, 99(10):2061-2069.
74. Egge KH, Thorgersen EB, Pischke SE, Lindstad JK, Anne Pharo A, Bongoni AK, **Rieben R**, Nunn MA, Barratt-Due A, Mollnes TE. Organ inflammation in porcine Escherichia coli sepsis is markedly attenuated by combined inhibition of C5 and CD14. *Immunobiology* 2015, 220(8):999-1005.
73. Ahrens HE, Petersen B, Herrmann D, Lucas-Hahn A, Hassel P, Ziegler M, Kues WA, Baulain U, Baars W, Schwinzer R, Denner J, Rataj D, Werwitzke S, Tiede A, Bongoni AK, Garimella PS, Despont A, **Rieben R**, Niemann H. siRNA Mediated Knockdown of Tissue Factor Expression in Pigs for Xenotransplantation. *Am J Transplant* 2015, 15(5):1407-1414.

72. Bongoni AK, Kiermeir D, Denoyelle J, Jenni H, Burlak C, Seebach JD, Voegelin E, Constantinescu MA, **Rieben R**. Porcine extrahepatic vascular endothelial ASRG1 mediates platelet phagocytosis in vitro and in human-to-pig ex vivo xenoperfusion. *Transplantation* 2015, 99(4):693-701.
71. Gajanayake T, Olariu R, Leclère FM, Dhayani A, Yang Z, Bongoni AK, Banz Y, Constantinescu MA, Karp JM*, Vemula PK*, **Rieben R***, Vögelin E. A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft. *Sci Transl Med* 2014, 6:249ra110.
*co-corresponding authors
70. Bongoni AK, Kiermeir D, Jenni H, Bähr A, Ayares D, Klymiuk N, Wolf E, Voegelin E, Constantinescu MA, Seebach JD, **Rieben R**. Complement dependent early immunological responses during ex vivo xenoperfusion of hCD46/HLA-E double transgenic pig forelimbs with human blood. *Xenotransplantation* 2014, 21(3):230-243.
69. Dührkop C, **Rieben R**. Refinement of tourniquet-induced peripheral ischemia/reperfusion injury in rats: Comparison of 2h vs. 24h reperfusion. *Laboratory Animals* 2014, 48(2):143-154.
68. Dührkop C, Denoyelle J, Shaw S, **Rieben R**. Use of dextran sulfate in tourniquet-induced skeletal muscle reperfusion injury. *J Surg Res* 2014, 187(1):150-161.
67. Wünsch A, Bähr A, Bongoni AK, Kemter E, Blutke A, Baars W, Haertle S, Zakhartchenko V, Kurome M, Kessler B, Faber C, Reichart B, Wanke R, Schwinzer R, Nagashima H, **Rieben R**, Ayares D, Wolf E, Klymiuk N. Regulatory sequences of the porcine THBD gene facilitate endothelial-specific expression of bioactive human thrombomodulin in single- and multitransgenic pigs. *Transplantation* 2014, 97(2):138-147.
66. Schweizer DF, Schweizer R, Zhang S, Kamat P, Contaldo C, **Rieben R**, Eberli D, Giovanoli P, Erni D, Plock JA. Botulinum toxin A and B raise blood flow and increase survival of critically ischemic skin flaps. *J Surg Res* 2013, 184:1205–1213.
65. Bongoni AK, Kiermeir D, Jenni H, Wünsch A, Bähr A, Ayares D, Seebach JD, Wolf E, Klymiuk N, Constantinescu MA, Vögelin E, **Rieben R**. Activation of the Lectin Pathway of Complement in Pig-to-Human Xenotransplantation Models. *Transplantation* 2013, 96(9):791-799.
64. Khattab AA, Stieger S, Kamat PJ, Vandenberghe S, Bongoni A, Stone GW, Seiler C, Meier B, Hess OM, **Rieben R**. Effect of pressure-controlled intermittent coronary sinus occlusion (PICSO) on myocardial ischaemia and reperfusion in a closed-chest porcine model. *EuroIntervention* 2013, 9:398–406.
63. Barratt-Due A, Thorgersen EB, Egge K, Pischke S, Sokolov A, Hellerud BC, Lindstad JK, Pharo A, Bongoni AK, **Rieben R**, Nunn M, Scott H, Mollnes TE. Combined inhibition of complement C5 and CD14 markedly attenuates inflammation, thrombogenicity, and hemodynamic changes in porcine sepsis. *J Immunol* 2013, 191:819–827.
62. Bongoni AK, Lanz J, **Rieben R**, Banz Y. Development of a bead-based multiplex assay for the simultaneous detection of porcine inflammation markers using xMAP technology. *Cytometry A* 2013, 83:636–647.
61. Ruder TD, Ebert LC, Khattab AA, **Rieben R**, Thali MJ, Kamat P. Edema is a sign of early acute myocardial infarction on post-mortem magnetic resonance imaging. *Forensic Sci Med Pathol* 2013, 9(4):501-505.

60. Müller S, Constantinescu MA, Kiermeir DM, Gajanayake T, Bongoni AK, Vollbach FH, Meoli M, Plock J, Jenni H, Banic A, **Rieben R***, Vögelin E. Ischemia/reperfusion injury of porcine limbs after extracorporeal perfusion. *J Surg Res* 2013; 181:170–182.
*corresponding author
59. Leclère FMP, Lewbart GA, **Rieben R**, Vögelin E. Microsurgery and liver research: Lumbricus terrestris, a reliable animal model for training? *Clin Res Hepatol Gastroenterol* 2013; 37:166–170.
58. Duehrkop C, Banz Y, Spirig R, Miescher S, Nolte MW, Spycher M, Smith RAG, Sacks SH, **Rieben R**. C1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage. *PLoS ONE* 2013; 8:e72059.
57. Spirig R, Schaub A, Kropf A, Miescher S, Spycher MO, **Rieben R**. Reconstituted high-density lipoprotein modulates activation of human leukocytes. *PLoS One* 2013; 8(8), e71235.
56. Kamat P, Juon B, Jossen B, Gajanayake T, **Rieben R***, Vögelin E. Assessment of endothelium and inflammatory response at the onset of reperfusion injury in hand surgery. *J Inflamm (Lond)* 2012; 9:18–28.
*corresponding author
55. Veres-Nyeki KO, **Rieben R**, Spadavecchia C, Bergadano A. Pancuronium dose refinement in experimental pigs used in cardiovascular research. *Vet Anaest Analg* 2012; 39(5):529–532.
54. Banz Y, Hess OM, Meier P, Korchagina EY, Gordeeva EA, Robson SC, Gajanayake T, Csizmadia E, Mettler D, Haeberli A, Bovin NV, **Rieben R**. Evaluation of multimeric tyrosine-O-sulfate as a cytoprotectant in an in vivo model of acute myocardial infarction in pigs. *Cardiology* 2012; 121:59–70.
53. Jenni H, Rheinberger J, Czerny M, Gygax E, **Rieben R**, Krähenbühl E, Carrel T, Stalder M. Autotransfusion system or integrated automatic suction device in minimized extracorporeal circulation: influence on coagulation and inflammatory response. *Eur J Cardiothorac Surg* 2011; 39(5): e139–43.
52. Pochechueva T, Chinarev A, Spengler M, Korchagina E, Heinzelmann-Schwarz V, Bovin N, **Rieben R**. Multiplex suspension array for human anti-carbohydrate antibody profiling. *Analyst* 2011; 136:560–569.
51. Spirig R, Djafarzadeh S, Regueira T, Shaw SG, von Garnier C, Takala J, Jakob SM, **Rieben R**, Lepper PM. Effects of TLR agonists on the hypoxia-regulated transcription factor HIF-1alpha and dendritic cell maturation under normoxic conditions. *PLoS One* 2010 5(6):e0010983. 2.81
50. Millard AL, Spirig R, Mueller NJ, Seebach JD, **Rieben R**. Inhibition of direct and indirect TLR-mediated activation of human NK cells by low molecular weight dextran sulfate. *Mol Immunol* 2010 47(14):2349–2358.
49. Constantinescu MA, Knall E, Xu X, Kiermeir DM, Jenni HJ, Gygax E, **Rieben R**, Banic A, Vögelin E. Preservation of amputated extremities by extracorporeal blood perfusion; a feasibility study in a porcine model. *J Surg Res* 2011; 171:291–299.
48. Spycher M, Matozan K, Minnig K, Zehnder R, Miescher S, Hoefferer L, **Rieben R**. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations. *Vox Sang* 2009 97(4):348–354.

47. Spirig R, Potapova I, Shaw-Boden J, Tsui J, **Rieben R**, Shaw SG. TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. *Mol Immunol* 2009 46(15):3178-3182.
46. Banz Y, Gajanayake T, Matozan K, Yang Z, **Rieben R**. Dextran sulfate modulates MAP kinase signaling and reduces endothelial injury in a rat aortic clamping model. *J Vasc Surg* 2009 50(1):161-170.
45. Gajanayake T, Sawitzki B, Matozan K, Korchagina EY, Lehmann M, Volk HD, **Rieben R**. Dextran Sulfate Facilitates Anti-CD4 mAb-Induced Long-Term Rat Cardiac Allograft Survival After Prolonged Cold Ischemia. *Am J Transplant* 2008 8(6):1151-1162.
44. Spirig R, van Kooten C, Obregon C, Nicod L, Daha MR, **Rieben R**. The Complement Inhibitor Low Molecular Weight Dextran Sulfate Prevents TLR4-Induced Phenotypic and Functional Maturation of Human Dendritic Cells. *J Immunol* 2008 181(2):878-890.
43. Banz Y, **Rieben R***, Zobrist C, Meier P, Shaw S, Lanz J, Carrel T, Berdat P. Addition of dextran sulfate to blood cardioplegia attenuates reperfusion injury in a porcine model of cardiopulmonary bypass. *Eur J Cardiothorac Surg* 2008 34(3):653-660.
*corresponding author
42. Stüssi G, Müller RJ, Passweg J, Schanz U, **Rieben R**, Seebach JD. ABO blood group incompatible hematopoietic stem cell transplantation and xenograft rejection. *Swiss Med Wkly* 2007 137(Suppl. 155):101S-108S.
41. Obukhova P, **Rieben R**, Bovin NV. Normal human serum contains high levels of anti Gal α 1-4GlcNAc antibodies. *Xenotransplantation* 2007 14(6): 627-635.
40. Banz Y, Hess OM, Robson SC, Csizmadia E, Mettler D, Meier P, Haeberli A, Shaw S, Smith RA, **Rieben R**. Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. *Cardiovascular Research* 2007 76(3):482-493.
39. Tanner H, Mohacsi P, Fuller-Bicer GA, **Rieben R**, Meier B, Hess O, Hullin R. Cytokine activation and disease progression in patients with stable moderate chronic heart failure. *J Heart Lung Transplant* 2007 26(6):622-629.
38. Baumann BC, Stüssi G, Huggel K, Hawley RJ, **Rieben R**, and Seebach JD. Reactivity of human natural antibodies to endothelial cells from Gal alpha(1,3) Gal-deficient pigs. *Transplantation* 2007 83(2):193-201.
37. Banz Y, Hess OM, Robson SC, Mettler D, Meier P, Haeberli A, Csizmadia E, Korchagina EY, Bovin NV, **Rieben R**. Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischemia/reperfusion injury. *Eur Heart J* 2005 26(21):2334-2343.
36. Stüssi G, Huggel K, Lutz HU, Schanz U, **Rieben R**, Seebach JD. Isotype-specific detection of ABO blood group antibodies using a novel, flow cytometric method. *Br J Haematol* 2005 130(6):954-963.
35. Banz Y, Cung T, Korchagina EY, Bovin NV, Haeberli Y, **Rieben R**. Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole blood. *Xenotransplantation* 2005 12(6):434-443.

34. Baumann BC, Forte P, Hawley RJ, **Rieben R**, Schneider MKJ, Seebach JD. Lack of Gal α (1-3)Gal expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. *J Immunol* 2004 172(10):6460-6467.
33. Laumonier T, Walpen AJ, Matozan KM, Korchagina EY, Bovin NV, Haeberli A, Mohacsi PJ, **Rieben R**. Multimeric tyrosine sulfate acts as an endothelial cell protectant and prevents complement activation in xenotransplantation models. *Xenotransplantation* 2004 11(3):262-268.
32. Laumonier T, Mohacsi PJ, Matozan KM, Banz Y, Haeberli A, Korchagina EY, Bovin NV, Vanhove B, **Rieben R**. Endothelial Cell protection by dextran sulfate: A novel strategy to prevent acute vascular rejection in xenotransplantation. *Amer J Transpl* 2004 4(2):181-187.
31. Walpen A, Laumonier T, Aebi C, Mohacsi PJ, **Rieben R**. Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum. *Xenotransplantation* 2004 11(2):141-148.
30. Laumonier T, Walpen AJ, Maurus CF, Mohacsi PJ, Matozan KM, Korchagina EY, Bovin NV, Vanhove B, Seebach JD, **Rieben R**. Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells. *Transplantation* 2003 76(5):838-843.
29. Pochechueva TV, Ushakova NA, Preobrazhenskaya ME, Nifant'ev NE, Tsvetkov YE, Sablina MA, Tuzikov AB, Bird MI, **Rieben R**, Bovin NV. P-selectin blocking potency of multimeric tyrosine sulfates in vitro and in vivo. *Bioorg Med Chem Lett* 2003 13(10):1709-1712.
28. Tsvetkov DE, Cheshev, PE, Tuzikov AB, Chinarev AA, Pazynina GV, Sablina MA, Gambaryan AS, Bovin NV, **Rieben R**, Shashkov AS, Nifant'ev NE. Neoglycoconjugates based on dendrimers poly(aminoamides). *Russian Journal of Bioorganic Chemistry* 2002 28(6):470-486.
27. Pierson RN 3rd, Loyd JE, Goodwin A, Majors D, Dummer JS, Mohacsi P, Wheeler A, Bovin N, Miller GG, Olson S, Johnson J, **Rieben R**, Azimzadeh A. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoabsorption, complement inhibition, and immunomodulatory therapy. *Transplantation* 2002 74(1):79-84.
26. Roos A, **Rieben R**, Faber-Krol MC, Daha MR. IgM-enriched human intravenous immunoglobulin strongly inhibits complement-dependent porcine cell cytotoxicity mediated by human xenoreactive antibodies. *Xenotransplantation* 2003 10(6):596-605.
25. Caliezi C, Zeerleider S, Redondo M, Regli B, Rothen H-U, Zürcher-Zenklusen R, **Rieben R**, Devay J, Hack CE, Lämmle B, Wuillemin WA. C1-inhibitor in patients with severe sepsis or septic shock: beneficial effect on renal dysfunction. *Crit Care Med* 2002 30(8):1722-1728.7.05
24. Walpen AJ, Mohacsi PJ, Frey C, Roos A, Daha MR, **Rieben R**. Activation of complement pathways in xenotransplantation: an in vitro study. *Transplant Immunol* 2002 9(2-4):271 280.
23. Mohacsi P, **Rieben R**, Sigurdsson G, Tschanz HU, Schaffner T, Nydegger UE, Carrel T. Successful management of a B-type cardiac allograft into an O-type man with 31/2 year clinical follow-up. *Transplantation* 2001 72(7):1328-1330.
22. Basker M, Alwayn IPJ, Buhler L, Harper D, Abraham S, Kruger Gray H, Awwad M, Down J, **Rieben R**, White-Scharf ME, Sachs DH, Thall A, Cooper DKC. Clearance of mobilized porcine peripheral blood progenitor cells is delayed by depletion of the phagocytic reticuloendothelial system in baboons. *Transplantation* 2001 72(7):1278-1285.

21. Gerber B, Tinguely C, Bovin NV, **Rieben R**, Nydegger UE. Differences between synthetic oligosaccharide immunoabsorbents in depletion capacity for xenoreactive anti-Gal α 1-3Gal antibodies from human serum. *Xenotransplantation* 2001; 8(2):106-114.
20. Fiorante P, Banz Y, Mohacsy PJ, Kappeler A, Wuillemin WA, Macchiarini P, Roos A, Daha MR, Schaffner T, Haeberli A, Mazmanian GM, **Rieben R**. Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models. *Xenotransplantation* 2001; 8(1):24-35.
19. **Rieben R**, Bovin NV, Korchagina EY, Oriol R, Nifant'ev NE, Tsvetkov DE, Daha MR, Mohacsy PJ, Joziasse DH. Xenotransplantation: in vitro analysis of synthetic α -galactosyl inhibitors of human anti-Gal α 1-3Gal IgM and IgG antibodies. *Glycobiology* 2000; 10(2):141-148.
18. Buonomano R, Tinguely C, **Rieben R**, Mohacsy PJ, Nydegger UE. Quantitation and characterization of anti-Gal α 1-3Gal antibodies in sera of 200 healthy persons. *Xenotransplantation* 1999; 6(3):173-180.
17. Tsvetkov DE, Cheshev PE, Tuzikov AB, Pzynina GV, **Rieben R**, Bovin NV, Nifant'ev NE. Synthesis of neoglycoconjugate dendrimers. *Mendeleev Commun* 1999; 47-50.
16. **Rieben R**, Roos A, Muizert Y, Tinguely C, Gerritsen AF, Daha MR. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. *Blood* 1999; 93(3):942-951.
15. Macchiarini P, Oriol R, Azimzadeh A, de Montpreville V, **Rieben R**, Bovin N, Darteville P. Evidence of human non-alpha Gal antibodies involved in the hyperacute rejection of pig lungs and their removal by pig organ perfusion. *J Thorac Cardiovasc Surg* 1998; 116(5):831-843.
14. Uetz-von Allmen E, Sturzenegger M, **Rieben R**, Rihs F, Frauenfelder A, Nydegger UE. Anti-ganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls. *Eur Neurol* 1998; 39(2):103-110.
13. Macchiarini P, Mazmanian GM, Oriol R, de Montpreville V, Dulmet E, Fattal S, Libert JM, Dubin S, Nochy D, **Rieben R**, Darteville P. Ex-vivo lung model of pig-to-human hyperacute xenograft rejection. *J Thorac Cardiovasc Surg* 1997; 114(3):315-325.
12. **Rieben R**, Korchagina EY, Bovin NV, Daha MR. Specificity of monoclonal antibodies against ABH- and related structures tested by ELISA with synthetic glycoconjugates. *Transf Clin Biolog* 1997; 1:47-54.
11. Friedli F, **Rieben R**, Wegmüller E, Moerenhout M, Nydegger UE. Normal levels of allo- but increased levels of potentially autoreactive antibodies against ABO histo-blood group antigens in AIDS patients. *Clin Immunol Immunopathol* 1996; 80(1):96-100.
10. **Rieben R**, Frauenfelder A, Nydegger UE. Spectrotype analysis of human ABO antibodies: evidence for different clonal heterogeneity of IgM, IgG, and IgA antibody populations. *Vox Sang* 1996; 70:104-111.
9. **Rieben R**, von Allmen E, Korchagina EY, Nydegger UE, Neethling, FA, Kujundzic M, Koren E, Bovin NV, Cooper DKC. Detection, immunoabsorption, and inhibition of cytotoxic activity of anti-alpha Gal antibodies using newly developed substances with synthetic Gal alpha1-3 Gal disaccharide epitopes. *Xenotransplantation* 1995; 2:98-106.
8. **Rieben R**, Korchagina EY, von Allmen E, Kremer Hovinga J, Lämmle B, Jungi T, Bovin NV, Nydegger UE. In vitro evaluation of the efficacy and biocompatibility of new, synthetic ABO immunoabsorbents. *Transplantation* 1995; 60(5):425-430.

7. von Allmen E, **Rieben R**, Nydegger UE. Development of a C1q-ABO-ELISA to measure C1 binding by human anti-A alloantibodies. *J Immunol Methods* 1994;171(1):85-92.2.10.
6. Auf der Maur C, Hodel M, Nydegger UE, **Rieben R**. Age-dependency of ABO histo-blood group antibodies - reexamination of an old dogma. *Transfusion* 1993;33(11):915-918.
5. **Rieben R**, Tucci M, Nydegger UE, Zubler RH. Self tolerance to human-A and human-B histo-blood group antigens exists at the B-cell level and cannot be broken by potent polyclonal B-cell activation in vitro. *Eur J Immunol* 1992;22(10):2713-2717.
4. **Rieben R**, Frauenfelder A, Nydegger UE. Naturally occurring ABO antibodies - long-term stable, individually distinct anti-A IgG spectrotypes. *Eur J Immunol* 1992;22(8):2129-2133.
3. Hasler CR, **Rieben R**, Buchs JP, Nydegger UE. Comparison between the levels of anti-A/B IgM/G antibodies in paired mother/child serum samples. *Transfus Sci* 1992;13(1):113-118.
2. **Rieben R**, Buchs JP, Flückiger E, Nydegger UE. Antibodies to histo-blood group substances A and B: agglutination titers, Ig class, and IgG subclasses in healthy persons of different age categories. *Transfusion* 1991;31(7):607-15.
1. **Rieben R**, Blaser K. Quantification of IgG and IgG4 antibodies to bee venom phospholipase A2 by competitive inhibition in ELISA. *J Immunol Methods* 1989;119(1):1-8.

Reviews, Book Sections, Case Reports, Letters, Editorials

26. Sfriso R, **Rieben R**. 3D Cell-Culture Models for the Assessment of Anticoagulant and Anti-Inflammatory Properties of Endothelial Cells. Methods in Molecular Biology. Springer Protocols. **2020**;2110:83-97
25. Puga Yung G, **Rieben R**, Bühler L, Schuurman, HJ, Seebach JD. Xenotransplantation: where do we stand in 2016? Swiss Medical Weekly 2017, 147:w14403.
24. Cowan P, **Rieben R**. Modifying the Glycome in Pigs for Xenotransplantation. Transplantation 2016, 100(3):485-486.
23. Ahrens HE, Petersen B, Herrmann D, Schwinzer R, Rataj D, Tiede A, Winkler M, Ramakers W, Bongoni A, **Rieben R**, Niemann H. Experimental approaches towards overcoming the acute vascular rejection during pig-to-primate xenotransplantation. Züchtungskunde 2016, 88(1):32-51.
22. Duehrkop C, **Rieben R**. Ischemia/reperfusion injury: Effect of simultaneous inhibition of plasma cascade systems versus specific complement inhibition. Biochim Pharmacol 2014, 88(1):12–22.
21. Banz Y, **Rieben R**. Role of complement and perspectives for intervention in ischemia-reperfusion damage. Annals of Medicine 2012, 44(3):205-217.
20. Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, **Rieben R**. Intravenous immunoglobulins – understanding properties and mechanisms. Clin Exp Immunol 2009 158(Suppl 1):2-13.
19. Spirig R, Gajanayake T, Korsgren O, Nilsson B, **Rieben R**. Low molecular weight dextran sulfate as complement inhibitor and cytoprotectant in solid organ and islet transplantation. Mol Immunol 2008 45(16):4084-4094.
18. Banz Y, **Rieben R**. Exploring natural anticoagulation by endothelial cells: A novel in vitro model. ALTEX 2007 24(special issue):9-11.
17. Banz Y, **Rieben R**. Exploring the natural anticoagulation by endothelial cells: A novel in vitro model. 3R-Info-Bulletin no. 34, January 2007.
16. Stüssi G, Müller RJ, Passweg J, Schanz U, **Rieben R**, Seebach JD. ABO blood group incompatible hematopoietic stem cell transplantation and xenograft rejection. Swiss Med Wkly 2007 137(1-2):13-20.
15. Banz Y, **Rieben R**. Endothelial cell protection in xenotransplantation: looking after a key player in rejection. Xenotransplantation 2006 13(1):19-30.
14. Nydegger UE, **Rieben R**. AB0-, nicht aber HLA-Gewebemerkmale schaffen es in die Tagespresse. Schweiz Med Forum 2005 5:1283–1284.
13. Nydegger UE, Tevaeearai H, Berdat P, **Rieben R**, Carrel T, Mohacs P, Flegel WA. Histoblood group antigens as allo- and autoantigens. Ann N Y Acad Sci 2005 1050:40-51.4.71.
12. **Rieben R**, Seebach JD. Xenograft rejection: IgG(1), complement and NK cells team up to activate and destroy the endothelium. Trends Immunol 2005 26(1):2-5.

11. Nydegger UE, **Rieben R**, Carrel T, Mohacsi P. Solid organ transplantation across the ABO histo-blood group barrier: a case report. *Transplant Proc.* 2004;36:1554-7.
10. Nydegger UE, **Rieben R**, Mohacsi PJ. Current precision of immunological extracorporeal plasma treatment. *Transfus Apheresis Sci* 2001;24(1):39-47.
9. **Rieben R**. Xenotransplantation – Beteiligungserfahrung Biotech, 4. EU-Forschungsrahmenprogramm. *Euroscope-CH* 2000;79:10-11.
8. **Rieben R**. Xenotransplantationsforschung in der Schweiz - Plädoyer für eine interdisziplinäre Zusammenarbeit. In: Potential and risk of xenotransplantation / Potential und Risiken der Xenotransplantation - Was Experten dazu meinen (Seebach JD, Candinas D, Largiader F, eds.) Luce Verlag, Murten 2000; pp. 158–163.
7. Nydegger UE, **Rieben R**, Lämmle B. Biocompatibility in transfusion medicine. *Transfusion Sci* 1996;17(4): 10-15.
6. Nydegger UE, **Rieben R**. Combined use of plasma exchange and intravenous immunoglobulins. *Ann Med Int (Paris)* 1994;145(5):287-292.
5. Zubler RH, Tucci A, **Rieben R**, Matthes T, Nydegger UE. Quantification of autoreactive lymphocytes in health and disease. In: Autoimmunity: Physiology and Disease (Cautinho A and Kazatchkine MD, eds.) Wiley-Liss Inc., New York 1994; pp. 173-190.
4. Nydegger UE, **Rieben R**, Kazatchkine MD. Intravenöse Immunglobulintherapie als Beeinflussungsmöglichkeit von autoimmunen Prozessen. In: Infektionen und Autoimmunerkrankungen II: Therapie mit Immunglobulinen und deren Derivaten (Salama A, Kurrle R eds.) Universitätsverlag Jena 1993; pp 15-27.
3. Nydegger U, **Rieben R**. Nouveaux aspects immunologiques et cliniques des groupes sanguins ABO. *Médecine et Hygiène* 1992;50:1334-1337.
2. Nydegger UE, **Rieben R**, Aeschbacher B. Biocompatibility of apheresis harness. *Transfus Sci* 1990;11(1):43-54.
1. Nydegger UE, **Rieben R**, Jungi TW. Synergy between plasma exchange and intravenous immunoglobulin. In: Nydegger UE, ed. Therapeutic Hemapheresis in the 1990's. Basel: Karger, 1990: 31-50. (Hässig A, Lundsgaard-Hansen P, eds. Current Studies in Hematology and Blood Transfusion; Vol 57).